1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Erdafitinib
Trade Name:
Balversa
Manufacturer/Distributor:
Janssen Inc.
Classification:
Protein kinase inhibitor
Antineoplastic agent
ATC Class:
L01XE - protein kinase inhibitor
Status:
active
Notice of Compliance (yyyy/mm/dd):
2019/10/24 (NOC/C)
Date Marketed in Canada (yyyy/mm/dd):
2019/12/09
Presentation:
Tablet: 3 mg. DIN: 02493217
Tablet: 4 mg. DIN: 02493225
Tablet: 4 mg, kit. DIN: 02493241
Tablet: 5 mg. DIN: 02493233
Comments:
For treatment of advanced or metastatic urothelial carcinoma in adult patients.
NOC with conditions pending results of trials to verify clinical benefit.
Back to:
Drug Product Listings 
